Cover Image
Market Research Report

Immune Thrombocytopenia (ITP) - Market Insights, Epidemiology, and Market Forecast - 2028

Published by DelveInsight Business Research LLP Product code 915407
Published Content info 230 Pages
Delivery time: 1-2 business days
Price
Back to Top
Immune Thrombocytopenia (ITP) - Market Insights, Epidemiology, and Market Forecast - 2028
Published: November 1, 2019 Content info: 230 Pages
Description

DelveInsight's 'Immune thrombocytopenia (ITP)- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of ITP in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Most of children with newly diagnosed ITP will develop chronic disease. Because of the high impact of ITP on a child's everyday life and activities, as well as to decide whether treatment has to be instituted to influence the clinical course of ITP, it is of clinical significance if the course of the disease could be predicted at time of diagnosis.

Our forecasting model has defined the prevalent population of Chronic Immune Thrombocytopenia (ITP) in children & adults. Chronic ITP patient inclusive of both primary ITP and secondary ITP. Approximately 70-75% of patient are refractory to first line therapies (corticosteroids/IVIG & others) and take second line therapies. As per the analysis, we have found that approximately 60-65% patients are refractory to second line treatment and take third line treatment.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Immune thrombocytopenia (ITP) - Disease Understanding and Treatment Algorithm

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function.

Immune thrombocytopenia (ITP) is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).

Immune thrombocytopenia (ITP) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, Total Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM, and Gender-specific Diagnosed Prevalent Cases of Immune thrombocytopenia (ITP) in 7MM) scenario of Immune thrombocytopenia (ITP) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total diagnosed cases of Immune thrombocytopenia (ITP) were found out to be approximately 147,174 in 2017, in the 7MM. The number of Immune thrombocytopenia (ITP) cases in the 7MM is expected to increase during the study period of 2017-2028.Immune thrombocytopenia (ITP) Drug Chapters

Broadly, two categories of agents are available for the treatment of ITP: those that rapidly and transiently interfere with the process of platelet destruction for management of acute bleeding or bleeding risk (front-line therapies), and those with the potential to provide a more durable improvement in the platelet count (second-line therapies).

The first-line options for therapy of ITP disease includes use of corticosteroids, IVIG, and anti-D immunoglobulin. There are three classes of second-line therapies that includes: splenectomy, rituximab, and the thrombopoietin receptor agonists (TPO-RA). The US Food and Drug Administration (FDA) have approved three TPO-RA therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). However for Europe and Japan, only two TPO-RAs is approved i.e. nplate and promacta. Promacta and nplate are going to lose their patent in 2020 in the US, and in Europe and Japan, nplate will lose the patent in 2019 while promacta will lose patent in 2025.

According to DelveInsight's analysis, Doptelet will generate USD 15.50 million in 2019 in the United States. Promacta was approved in Japan in 2010, for the treatment of ITP in adults. While, Nplate was approved in japan in 2011 for the treatment of ITP in adults. The market of both the drugs will experience a decline due to their patent expiry in the year, 2019 and 2025, respectively.

Immune thrombocytopenia (ITP) Market Outlook

According to DelveInsight, the market of Immune thrombocytopenia (ITP) in 7MM was found to be approximately USD 2,678.0 million in 2017. Among the EU5 countries, in 2017, United Kingdom had the highest market size with approximately USD 262.00 million, while Spain had the lowest market size for Immune thrombocytopenia (ITP) with approximately USD 121.00 million.

Immune thrombocytopenia (ITP) Drugs Uptake

The dynamics of Immune thrombocytopenia (ITP) market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. The therapies which are under development for the treatment of ITP are BT595 (Biotest); UCB7665 (UCB Biopharma) and ARGX-113 (Argenx BVBA). With the expected launch of upcoming therapies, BT595 (Biotest) in 2021; Rozanolixizumab (UCB7665: UCB Biopharma) in and Efgartigimod (ARGX-113: Argenx BVBA) in 2023, the market will experience a significant growth.

Immune thrombocytopenia (ITP) Report Insights

  • Patient Population by total diagnosed cases
  • Gender-specific diagnosed population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Immune thrombocytopenia (ITP) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Immune thrombocytopenia (ITP) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving ITP market
  • Organize sales and marketing efforts by identifying the best opportunities for ITP market
  • To understand the future market competition in the ITP market.
Table of Contents
Product Code: DIMI0663

Table of Contents

1. Key Insights

2. Immune Thrombocytopenia (ITP) Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2017
  • 2.2. Market Share (%) Distribution of Immune Thrombocytopenia (ITP) in 2028

3. Immune Thrombocytopenia (ITP): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Etiology of Immune Thrombocytopenia (ITP)
  • 3.3. Signs and Symptoms of Immune Thrombocytopenia (ITP)
  • 3.4. Types of Immune Thrombocytopenia (ITP)
  • 3.5. Pathophysiology of Immune Thrombocytopenia (ITP)
  • 3.6. Pathogenesis of Immune Thrombocytopenia (ITP)
  • 3.7. Genetic background and environmental factors related to ITP
  • 3.8. Biomarkers associated with Immune Thrombocytopenia (ITP)
  • 3.9. Diagnosis of Immune Thrombocytopenia
  • 3.10. Diagnostic Guidelines of Immune Thrombocytopenia
    • 3.10.1. 2011 Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
    • 3.10.2. The American Society of Hematology 2011 evidence-based practice guideline for Immune Thrombocytopenia
    • 3.10.3. Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
    • 3.10.4. Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of Immune Thrombocytopenia (ITP)
  • 4.3. 7MM Diagnosed Prevalent Patient Population of Immune Thrombocytopenia

5. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)

  • 5.1. United States Epidemiology
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States
    • 5.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in the United States
    • 5.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States
  • 5.2. EU5 Epidemiology
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Germany
      • 5.2.1.3. Diagnosed Prevalence of Immune Thrombocytopenia in Germany
      • 5.2.1.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in France
      • 5.2.2.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
      • 5.2.2.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Prevalent Cases of Immune Thrombocytopenia in Italy
      • 5.2.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Italy
      • 5.2.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Spain
      • 5.2.4.3. Diagnosed Prevalence of Immune Thrombocytopenia in Spain
      • 5.2.4.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in the United Kingdom
      • 5.2.5.3. Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
      • 5.2.5.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom
  • 5.3. Japan Epidemiology
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan
    • 5.3.3. Diagnosed Prevalence of Immune Thrombocytopenia in Japan
    • 5.3.4. Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan

6. Treatment and Management of Immune Thrombocytopenia (ITP)

  • 6.1. Treatment Algorithm of Immune Thrombocytopenia (ITP)
  • 6.2. First-Line Treatments of Immune Thrombocytopenia
  • 6.3. Second-Line Treatments of Immune Thrombocytopenia
  • 6.4. Third-Line Treatments of Immune Thrombocytopenia
  • 6.5. Treatment Guidelines
    • 6.5.1. American Society of Hematology Guidelines for the Management of Newly Diagnosed ITP in Adults and Children
    • 6.5.2. Japanese practice guidelines for newly diagnosed childhood idiopathic thrombocytopenic purpura
    • 6.5.3. British Journal of Hematology: Guidelines for the Investigation and Management of Idiopathic thrombocytopenic Purpura in Adults, Children and in Pregnancy
    • 6.5.4. Spanish Society of Hematology and Hemotherapy: Guidelines for diagnosis, treatment and monitoring of the PTI

7. Unmet Needs

8. Marketed Drugs

  • 8.1. Key Cross Competition
  • 8.2. Octagam: Octapharma USA
    • 8.2.1. Product Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Safety and Efficacy of Octagam
    • 8.2.4. Side effects of Octagam
    • 8.2.5. Product Profile
  • 8.3. Nplate (AMG-531): Amgen
    • 8.3.1. Product Description
    • 8.3.2. Regulatory Milestones
    • 8.3.3. Advantages & Disadvantages
    • 8.3.4. Safety and Efficacy of Nplate
    • 8.3.5. Side effects of Nplate
    • 8.3.6. Product Profile
  • 8.4. Privigen: CSL Behring
    • 8.4.1. Product Description
    • 8.4.2. Regulatory Milestones
    • 8.4.3. Advantages & Disadvantages
    • 8.4.4. Safety and Efficacy of Privigen
    • 8.4.5. Side effects of Privigen
    • 8.4.6. Product Profile
  • 8.5. Rhophylac: CSL Behring
    • 8.5.1. Product Description
    • 8.5.2. Regulatory Milestones
    • 8.5.3. Advantages & Disadvantages
    • 8.5.4. Safety and Efficacy of Rhophylac
    • 8.5.5. Side effects of Rhophylac
    • 8.5.6. Product Profile
  • 8.6. Doptelet (Avatrombopag): Dova Pharmaceuticals
    • 8.6.1. Drug Description
    • 8.6.2. Regulatory Milestones
    • 8.6.3. Other Development Activities
    • 8.6.4. Advantages and Disadvantages
    • 8.6.5. Safety and efficacy
    • 8.6.6. Product Profile
  • 8.7. Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
    • 8.7.1. Drug Description
    • 8.7.2. Regulatory Milestones
    • 8.7.3. Advantages and Disadvantages
    • 8.7.4. Clinical Development
    • 8.7.5. Safety and efficacy
    • 8.7.6. Product Profile
  • 8.8. Rituximab: Zenyaku Kogyo/Biogen Idec
    • 8.8.1. Product Description
    • 8.8.2. Regulatory Milestones
    • 8.8.3. Advantages & Disadvantages
    • 8.8.4. Product Profile
  • 8.9. Promacta (eltrombopag): Novartis
    • 8.9.1. Product Description
    • 8.9.2. Regulatory Milestones
    • 8.9.3. Advantages & Disadvantages
    • 8.9.4. Safety and efficacy
    • 8.9.5. Product Profile
  • 8.10. Gammaplex: Bio Products Laboratory's
    • 8.10.1. Product Description
    • 8.10.2. Regulatory Milestones
    • 8.10.3. Advantages and Disadvantages
    • 8.10.4. Safety and Efficacy of Rhophylac
    • 8.10.5. Product Profile
  • 8.11. Takecab: Takeda Pharmaceutical Company Limited
    • 8.11.1. Product Description
    • 8.11.2. Regulatory Milestones
    • 8.11.3. Product Profile
  • 8.12. Nexium Capsules: AstraZeneca
    • 8.12.1. Product Description
    • 8.12.2. Regulatory Milestones
    • 8.12.3. Product Profile

9. Emerging Drugs

  • 9.1. Key Cross Competition
  • 9.2. BT-595: Biotest
    • 9.2.1. Drug Description
    • 9.2.2. Other Development Activities
    • 9.2.3. Advantages and Disadvantages
    • 9.2.4. Clinical Development
    • 9.2.5. Clinical Trials Information
    • 9.2.6. Product Profile
  • 9.3. GC5107A: GC Pharma
    • 9.3.1. Product Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Clinical Trials Information
    • 9.3.5. Safety and Efficacy
    • 9.3.6. Product Profile
  • 9.4. LIV-Gamma SN Inj.: SK Plasma
    • 9.4.1. Product Description
    • 9.4.2. Advantages and Disadvantages
    • 9.4.3. Clinical Development
    • 9.4.4. Clinical Trials Information
    • 9.4.5. Product Profile
  • 9.5. Hetrombopag Olamine: Jiangsu HengRui Medicine
    • 9.5.1. Product Description
    • 9.5.2. Advantages and Disadvantages
    • 9.5.3. Clinical Development
    • 9.5.4. Clinical Trials Information
    • 9.5.5. Product Profile
  • 9.6. Efgartigimod (ARGX-113): Argenx
    • 9.6.1. Product Description
    • 9.6.2. Other Development Activities
    • 9.6.3. Clinical Development
    • 9.6.4. Clinical Trials Information
    • 9.6.5. Safety and efficacy
    • 9.6.6. Product Profile
  • 9.7. SKI-O-703: Genosco (a US-based subsidiary of Korean bio company Oscotec)
    • 9.7.1. Product Description
    • 9.7.2. Advantages and Disadvantages
    • 9.7.3. Clinical Development
    • 9.7.4. Clinical Trials Information
    • 9.7.5. Product Profile
  • 9.8. KZR-616: Kezar Life Sciences
    • 9.8.1. Product Description
    • 9.8.2. Other Developmental Activities
    • 9.8.3. Clinical Development
    • 9.8.4. Clinical Trials Information
    • 9.8.5. Product Profile
  • 9.9. Rozanolixizumab: UCB Biopharma
    • 9.9.1. Product Description
    • 9.9.2. Other Development Activities
    • 9.9.3. Clinical Development
    • 9.9.4. Clinical Trials Information
    • 9.9.5. Safety and efficacy
    • 9.9.6. Product Profile
  • 9.10. BMS-986004 (Letolizumab): Bristol-Myers Squibb
    • 9.10.1. Product Description
    • 9.10.2. Other Developmental Activities
    • 9.10.3. Clinical Development
    • 9.10.4. Clinical Trials Information
    • 9.10.5. Safety and Efficacy
    • 9.10.6. Product Profile
  • 9.11. PRN-1008: Principia Biopharma
    • 9.11.1. Drug Description
    • 9.11.2. Other Development Activities
    • 9.11.3. Advantages and Disadvantages
    • 9.11.4. Clinical Development
    • 9.11.5. Clinical Trials Information
    • 9.11.6. Safety and Efficacy
    • 9.11.7. Product Profile
  • 9.12. PRTX-100: Protalex
    • 9.12.1. Drug Description
    • 9.12.2. Regulatory Milestones
    • 9.12.3. Advantages and Disadvantages
    • 9.12.4. Clinical Development
    • 9.12.5. Clinical Trials Information
    • 9.12.6. Safety and Efficacy
    • 9.12.7. Product Profile

10. Immune Thrombocytopenia (ITP): 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Immune Thrombocytopenia (ITP) in the 7MM
  • 10.3. Market Size of Immune Thrombocytopenia (ITP) by Therapies in the 7MM

11. Market Outlook: The United States

  • 11.1. United States Market Size
    • 11.1.1. The total Market size of Immune Thrombocytopenia (ITP)
    • 11.1.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in the United States

12. Market Outlook: Europe

  • 12.1. Germany
    • 12.1.1. Total Market size of Immune Thrombocytopenia (ITP)
    • 12.1.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in Germany
  • 12.2. France
    • 12.2.1. Total Market size of Immune Thrombocytopenia (ITP)
    • 12.2.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in France
  • 12.3. Italy
    • 12.3.1. Total Market size of Immune Thrombocytopenia (ITP)
    • 12.3.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in Italy
  • 12.4. Spain
    • 12.4.1. Total Market size of Immune Thrombocytopenia (ITP)
    • 12.4.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in Spain
  • 12.5. United Kingdom
    • 12.5.1. Total Market size of Immune Thrombocytopenia (ITP)
    • 12.5.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in the United Kingdom

13. Market Outlook: Japan

  • 13.1. Total Market size of Immune Thrombocytopenia (ITP)
  • 13.2. Market Size of Immune Thrombocytopenia (ITP) by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables

  • Table 1 The role of infections in ITP pathogenesis
  • Table 2 Idiopathic Thrombocytopenic Purpura in Children: Newly Diagnosed ITP
  • Table 3 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
  • Table 4 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
  • Table 5 Total Prevalent Population of Immune Thrombocytopenia in the United States (2017-2028)
  • Table 6 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
  • Table 7 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United States (2017-2028)
  • Table 8 Total Prevalent Population of Immune Thrombocytopenia in Germany (2017-2028)
  • Table 9 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
  • Table 10 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
  • Table 11 Total Prevalent Population of Immune Thrombocytopenia in France (2017-2028)
  • Table 12 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
  • Table 13 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
  • Table 14 Total Prevalent Population of Immune Thrombocytopenia in Italy (2017-2028)
  • Table 15 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
  • Table 16 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
  • Table 17 Total Prevalent Population of Immune Thrombocytopenia in Spain (2017-2028)
  • Table 18 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
  • Table 19 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
  • Table 20 Total Diagnosed Prevalent Population of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
  • Table 21 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
  • Table 22 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in the United Kingdom (2017-2028)
  • Table 23 Total Prevalent Population of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
  • Table 24 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
  • Table 25 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
  • Table 26 Sequence of Treatments for Adults with ITP
  • Table 27 Standard first-line therapy for ITP
  • Table 28 First-line treatment options in adults with newly diagnosed ITP
  • Table 29 Second- and third-line treatment options for adults with ITP
  • Table 30 Idiopathic Thrombocytopenic Purpura in Children
  • Table 31 Treatment options for newly diagnosed childhood ITP vs. platelet count and clinical manifestations in the 2004 guidelines
  • Table 32 List of Marketed Drugs Analysis (Table 1)
  • Table 33 List of Marketed Drugs Analysis (Table 2)
  • Table 34 List of Few Emerging Drugs Analysis
  • Table 35 BT-595, Clinical Trial Description, 2019
  • Table 36 GC5107A, Clinical Trial Description, 2019
  • Table 37 LIV-Gamma SN Inj., Clinical Trial Description, 2019
  • Table 38 Hetrombopag Olamine, Clinical Trial Description, 2019
  • Table 39 ARGX-113, Clinical Trial Description, 2019
  • Table 40 SKI-O-703, Clinical Trial Description, 2019
  • Table 41 KZR-616, Clinical Trial Description, 2019
  • Table 42 Rozanolixizumab, Clinical Trial Description, 2019
  • Table 43 BMS-986004, Clinical Trial Description, 2019
  • Table 44 PRN1008, Clinical Trial Description, 2019
  • Table 45 PRTX-100, Clinical Trial Description, 2019
  • Table 46 Market size of Immune Thrombocytopenia (ITP) by Region in USD Million (2017-2028)
  • Table 47 Market Size of Immune Thrombocytopenia by Therapies in 7MM,in USD Million (2017-2028)
  • Table 48 United States Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 49 Market Size of Immune Thrombocytopenia (ITP) by Therapies in the United States, in USD Million (2017-2028)
  • Table 50 Germany Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 51 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Germany, in USD Million (2017-2028)
  • Table 52 France Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 53 Market Size of Immune Thrombocytopenia (ITP) by Therapies in France, in USD Million (2017-2028)
  • Table 54 Italy Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 55 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Italy, in USD Million (2017-2028)
  • Table 56 Spain Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 57 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Spain, in USD Million (2017-2028)
  • Table 58 United Kingdom Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 59 Market Size of Immune Thrombocytopenia (ITP) by Therapies in the United Kingdom, in USD Million (2017-2028)
  • Table 60 Japan Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Table 61 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Japan, in USD Million (2017-2028)

List of Figures

  • Figure 1 Differences in B cell and T cell mechanisms in immune thrombocytopenia (ITP)
  • Figure 2 Signs and Symptoms of Immune Thrombocytopenia
  • Figure 3 Classification of Immune Thrombocytopenia (ITP)
  • Figure 4 ITP International Working Group proposed definitions of disease
  • Figure 5 Pathophysiology of cITP
  • Figure 6 Cellular pathogenic mechanisms in immune thrombocytopenia
  • Figure 7 Immune thrombocytopenia pathogenesis
  • Figure 8 Total Prevalent Patient Population of Immune Thrombocytopenia in 7MM (2017-2028)
  • Figure 9 Diagnosed Prevalent Patient Population of Immune Thrombocytopenia in the 7MM (2017-2028)
  • Figure 10 Total Prevalent Cases of Immune Thrombocytopenia in the United States (2017-2028)
  • Figure 11 Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
  • Figure 12 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United States (2017-2028)
  • Figure 13 Total Prevalent Cases of Immune Thrombocytopenia in Germany (2017-2028)
  • Figure 14 Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
  • Figure 15 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Germany (2017-2028)
  • Figure 16 Total Prevalent Cases of Immune Thrombocytopenia in France (2017-2028)
  • Figure 17 Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
  • Figure 18 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in France (2017-2028)
  • Figure 19 Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
  • Figure 20 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Italy (2017-2028)
  • Figure 21 Total Prevalent Cases of Immune Thrombocytopenia in Spain (2017-2028)
  • Figure 22 Diagnosed Prevalence of Immune Thrombocytopenia in Spain (2017-2028)
  • Figure 23 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Spain (2017-2028)
  • Figure 24 Total Prevalent Cases of Immune Thrombocytopenia in the United Kingdom (2017-2028)
  • Figure 25 Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
  • Figure 26 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in the United Kingdom (2017-2028)
  • Figure 27 Total Prevalent Cases of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
  • Figure 28 Diagnosed Prevalence of Immune Thrombocytopenia (ITP) in Japan (2017-2028)
  • Figure 29 Gender-Specific Diagnosed Prevalence of Immune Thrombocytopenia in Japan (2017-2028)
  • Figure 30 Therapeutic mechanisms of current ITP treatments
  • Figure 31 Therapeutic mechanisms of current ITP treatments
  • Figure 32 Treatment Algorithm of ITP In Adults
  • Figure 33 Treatment Algorithm of Chronic ITP In Children
  • Figure 34 Treatment Algorithm of Acute ITP In Children
  • Figure 35 Treatment Algorithm of ITP in Pregnancy
  • Figure 36 Newer therapies for immune thrombocytopenia refractory to first-line treatment in adults
  • Figure 37 Advantages and Disadvantages of the Principal Options for Second-Line Treatment of ITP
  • Figure 38 Unmet Needs
  • Figure 39 Market size of Immune Thrombocytopenia (ITP) by Region in USD Million (2017-2028)
  • Figure 40 Market Size of Immune Thrombocytopenia by Therapies in 7MM, in USD Million (2017-2028)
  • Figure 41 United States Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 42 Market Size of Immune Thrombocytopenia (ITP) by Therapies in the United States in USD Million (2017-2028)
  • Figure 43 Germany Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 44 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Germany, in USD Million (2017-2028)
  • Figure 45 France Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 46 Market Size of Immune Thrombocytopenia (ITP) by Therapies in France, in USD Million (2017-2028)
  • Figure 47 Italy Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 48 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Italy, in USD Million (2017-2028)
  • Figure 49 Spain Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 50 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Spain, in USD Million (2017-2028)
  • Figure 51 United Kingdom Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 52 Market Size of Immune Thrombocytopenia (ITP) by Therapies in the UK, in USD Million (2017-2028)
  • Figure 53 Japan Market Size of Immune Thrombocytopenia (ITP) in USD Million (2017-2028)
  • Figure 54 Market Size of Immune Thrombocytopenia (ITP) by Therapies in Japan, in USD Million (2017-2028)
  • Figure 55 Market Drivers
  • Figure 56 Market Barriers
Back to Top